Refractory cytopenias

Clinical course according to bone marrow cytology and cellularity

A. Riccardi, M. Giordano, M. Girino, M. Cazzola, C. M. Montecucco, E. Cassano, M. Danova, G. Ucci, A. Castello, A. Coci, E. Ascari

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

One hundred and one patients with refractory cytopenia were reviewed for morphological classification (using bone marrow, BM, imprints for cytology and Jamshidi biopsies for BM cellularity) and clinical course. Final diagnoses were: moderate aplastic anemia (MAA), myelodysplastic syndromes (MDS) and hypoplastic acute leukemia (HAL). Ninety-two patients received high dose testosterone enanthate (TE) as first treatment (starting dose=7-10 mg/week i.m. for at least three months). Median survival was significantly longer in MAA than in MDS and in HAL. Among MDS patients, those with primary acquired sideroblastic (AISA) and refractory (RA) anemia had median survival similar to those with MAA, but distinctly longer (p=0.01) than patients with RA with an excess of blasts (RAEB), RAEB in transformation (RAEBtr) and chronic myelomonocytic leukemia (CMMoL). Acute leukemia (AL) developed more rarely (p

Original languageEnglish
Pages (from-to)153-163
Number of pages11
JournalBlut
Volume54
Issue number3
DOIs
Publication statusPublished - Mar 1987

Fingerprint

Cell Biology
Aplastic Anemia
Myelodysplastic Syndromes
Bone Marrow
Leukemia
Sideroblastic Anemia
Leukemia, Myelomonocytic, Chronic
Refractory Anemia
Survival
Lymphocyte Activation
Biopsy
Therapeutics

Keywords

  • Androgen therapy
  • Bone marrow cellularity
  • FAB classification
  • Prognosis
  • Refractory cytopenias

ASJC Scopus subject areas

  • Hematology

Cite this

Refractory cytopenias : Clinical course according to bone marrow cytology and cellularity. / Riccardi, A.; Giordano, M.; Girino, M.; Cazzola, M.; Montecucco, C. M.; Cassano, E.; Danova, M.; Ucci, G.; Castello, A.; Coci, A.; Ascari, E.

In: Blut, Vol. 54, No. 3, 03.1987, p. 153-163.

Research output: Contribution to journalArticle

Riccardi, A, Giordano, M, Girino, M, Cazzola, M, Montecucco, CM, Cassano, E, Danova, M, Ucci, G, Castello, A, Coci, A & Ascari, E 1987, 'Refractory cytopenias: Clinical course according to bone marrow cytology and cellularity', Blut, vol. 54, no. 3, pp. 153-163. https://doi.org/10.1007/BF00320369
Riccardi, A. ; Giordano, M. ; Girino, M. ; Cazzola, M. ; Montecucco, C. M. ; Cassano, E. ; Danova, M. ; Ucci, G. ; Castello, A. ; Coci, A. ; Ascari, E. / Refractory cytopenias : Clinical course according to bone marrow cytology and cellularity. In: Blut. 1987 ; Vol. 54, No. 3. pp. 153-163.
@article{af9f6649dc254364beef4a87b2af4e28,
title = "Refractory cytopenias: Clinical course according to bone marrow cytology and cellularity",
abstract = "One hundred and one patients with refractory cytopenia were reviewed for morphological classification (using bone marrow, BM, imprints for cytology and Jamshidi biopsies for BM cellularity) and clinical course. Final diagnoses were: moderate aplastic anemia (MAA), myelodysplastic syndromes (MDS) and hypoplastic acute leukemia (HAL). Ninety-two patients received high dose testosterone enanthate (TE) as first treatment (starting dose=7-10 mg/week i.m. for at least three months). Median survival was significantly longer in MAA than in MDS and in HAL. Among MDS patients, those with primary acquired sideroblastic (AISA) and refractory (RA) anemia had median survival similar to those with MAA, but distinctly longer (p=0.01) than patients with RA with an excess of blasts (RAEB), RAEB in transformation (RAEBtr) and chronic myelomonocytic leukemia (CMMoL). Acute leukemia (AL) developed more rarely (p",
keywords = "Androgen therapy, Bone marrow cellularity, FAB classification, Prognosis, Refractory cytopenias",
author = "A. Riccardi and M. Giordano and M. Girino and M. Cazzola and Montecucco, {C. M.} and E. Cassano and M. Danova and G. Ucci and A. Castello and A. Coci and E. Ascari",
year = "1987",
month = "3",
doi = "10.1007/BF00320369",
language = "English",
volume = "54",
pages = "153--163",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Refractory cytopenias

T2 - Clinical course according to bone marrow cytology and cellularity

AU - Riccardi, A.

AU - Giordano, M.

AU - Girino, M.

AU - Cazzola, M.

AU - Montecucco, C. M.

AU - Cassano, E.

AU - Danova, M.

AU - Ucci, G.

AU - Castello, A.

AU - Coci, A.

AU - Ascari, E.

PY - 1987/3

Y1 - 1987/3

N2 - One hundred and one patients with refractory cytopenia were reviewed for morphological classification (using bone marrow, BM, imprints for cytology and Jamshidi biopsies for BM cellularity) and clinical course. Final diagnoses were: moderate aplastic anemia (MAA), myelodysplastic syndromes (MDS) and hypoplastic acute leukemia (HAL). Ninety-two patients received high dose testosterone enanthate (TE) as first treatment (starting dose=7-10 mg/week i.m. for at least three months). Median survival was significantly longer in MAA than in MDS and in HAL. Among MDS patients, those with primary acquired sideroblastic (AISA) and refractory (RA) anemia had median survival similar to those with MAA, but distinctly longer (p=0.01) than patients with RA with an excess of blasts (RAEB), RAEB in transformation (RAEBtr) and chronic myelomonocytic leukemia (CMMoL). Acute leukemia (AL) developed more rarely (p

AB - One hundred and one patients with refractory cytopenia were reviewed for morphological classification (using bone marrow, BM, imprints for cytology and Jamshidi biopsies for BM cellularity) and clinical course. Final diagnoses were: moderate aplastic anemia (MAA), myelodysplastic syndromes (MDS) and hypoplastic acute leukemia (HAL). Ninety-two patients received high dose testosterone enanthate (TE) as first treatment (starting dose=7-10 mg/week i.m. for at least three months). Median survival was significantly longer in MAA than in MDS and in HAL. Among MDS patients, those with primary acquired sideroblastic (AISA) and refractory (RA) anemia had median survival similar to those with MAA, but distinctly longer (p=0.01) than patients with RA with an excess of blasts (RAEB), RAEB in transformation (RAEBtr) and chronic myelomonocytic leukemia (CMMoL). Acute leukemia (AL) developed more rarely (p

KW - Androgen therapy

KW - Bone marrow cellularity

KW - FAB classification

KW - Prognosis

KW - Refractory cytopenias

UR - http://www.scopus.com/inward/record.url?scp=0023158834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023158834&partnerID=8YFLogxK

U2 - 10.1007/BF00320369

DO - 10.1007/BF00320369

M3 - Article

VL - 54

SP - 153

EP - 163

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 3

ER -